Renal Biomarkers Market to Grow with a CAGR of 7.25% through 2030
Rising healthcare expenditure is expected to drive the Global Renal Biomarkers Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Renal
Biomarkers Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2030F”, the Global Renal Biomarkers Market
stood at USD 1.31 billion in 2024 and is anticipated to grow with a CAGR of 7.25%
in the forecast period, 2026-2030. The global renal
biomarkers market has been steadily growing in recent years, driven by various
factors that highlight the increasing importance of renal function assessment
in healthcare. Renal biomarkers play a crucial role in the diagnosis,
prognosis, and management of kidney-related diseases and disorders. One of the
primary drivers of the global renal biomarkers market is the growing prevalence
of kidney diseases worldwide. Conditions such as chronic kidney disease (CKD),
acute kidney injury (AKI), and diabetic nephropathy have become increasingly
common due to factors like aging populations, sedentary lifestyles, and the
rising incidence of diabetes and hypertension. As the burden of kidney diseases
continues to rise, the demand for effective biomarker-based diagnostic and
monitoring tools has also increased. Advancements in diagnostic technologies have significantly
contributed to the growth of the renal biomarkers market. The development of
sensitive and specific assays for renal biomarkers has improved the accuracy of
kidney disease diagnosis and monitoring. Innovative techniques, such as mass
spectrometry and immunoassays, have enabled healthcare professionals to detect
renal biomarkers in blood and urine samples with high precision. These
technological advances have made early detection and intervention for kidney
diseases possible, driving market growth.
The healthcare industry has witnessed a
shift towards personalized medicine, wherein treatments are tailored to
individual patients based on their genetic makeup and specific health
conditions. Renal biomarkers play a pivotal role in personalized medicine,
helping physicians identify the most suitable treatment plans for patients with
kidney diseases. This approach not only enhances patient outcomes but also
drives demand for renal biomarker testing. Rising healthcare expenditure
across the globe has provided a substantial boost to the renal biomarkers
market. As governments and healthcare organizations allocate more resources to
address the growing burden of kidney diseases, there is a greater emphasis on
early diagnosis and effective disease management. This has led to increased
investments in diagnostic tests and technologies, including renal biomarkers,
which are critical for efficient patient care.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on " Global Renal Biomarkers Market”
Global Renal Biomarkers Market is segmented into product
type, technique, end user, regional distribution, and company.
Based on Technique, Enzyme-linked Immunosorbent Assay (ELISA) emerged as the dominating segment in the global market for Renal Biomarkers in 2024. ELISA is highly effective in diagnosing renal diseases due to its high sensitivity and specificity in detecting various biomarkers, even at low concentrations, which is common in kidney conditions. Compared to more expensive methods like Liquid Chromatography Mass Spectrometry (LC-MS), ELISA is cost-effective, making it accessible for routine clinical use, especially in resource-limited settings. Its simplicity and low requirement for specialized equipment make it widely used in both research and clinical practices. ELISA is scalable to handle large sample volumes, crucial for mass testing in clinical laboratories, and can be automated for high-throughput testing. With decades of use, ELISA has established itself as a trusted method for biomarker detection, including in kidney disease diagnostics. Its versatility extends beyond renal conditions, making it a go-to tool for a variety of medical tests. These advantages make ELISA the leading technique in the renal biomarkers market, especially for early detection and monitoring of chronic kidney disease (CKD).
Based on Region, the Asia Pacific region is expected to be fastest growing region during the forecast period in global Renal Biomarkers market. The growing prevalence of Chronic Kidney Disease (CKD) and other renal conditions, driven by factors such as aging populations, lifestyle changes, and increasing rates of diabetes and hypertension, is boosting demand for early detection and effective treatments. Countries across Asia Pacific, particularly China, India, and Japan, are significantly investing in healthcare system upgrades and the adoption of advanced technologies, including renal biomarkers, which are improving access to diagnostics and treatment. Regional governments are prioritizing healthcare innovation, providing funding and support for the development and commercialization of renal biomarkers. Both public and private sector R&D investments are driving the rapid advancement of new biomarkers and kidney disease treatments. Asia Pacific is becoming a key hub for global clinical trials, contributing to the growth of biomarkers in the market. These factors are propelling the region’s rapid expansion in the renal biomarkers market.
Major companies operating in Global Renal
Biomarkers Market are:
- Abbott Laboratories
- Beckman Coulter Inc. (Danaher
Corporation)
- bioMerieux SA
- BioPorto A/S
- Bio-Rad Laboratories Inc.
- Enzo Biochem Inc.
- F. Hoffmann-La Roche AG
- PerkinElmer Inc.
- Randox Laboratories Ltd.
- Siemens AG
- Thermo Fisher Scientific Inc.
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The global renal biomarkers market is experiencing
robust growth driven by a combination of factors, including the rising
prevalence of kidney diseases, advancements in diagnostic technologies, the
shift towards personalized medicine, increased healthcare expenditure, drug
development needs, and growing public awareness. As the healthcare industry
continues to evolve and prioritize kidney health, the renal biomarkers market
is expected to expand further, providing improved diagnostic and monitoring
solutions for kidney-related conditions,” said Mr. Karan Chechi, Research
Director of TechSci Research, a research-based management consulting firm.
“Renal Biomarkers Market By Product Type (Functional
Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated
Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury
Molecule-1, INTERLEUKIN-18, Others), By Technique (Enzyme-linked Immunosorbent
Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA),
Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid
Chromatography Mass Spectrometry (LC-MS)), By End user (Hospitals
& Clinics, Diagnostic Laboratory, Others), By Region, By
Competition Forecast & Opportunities, 2020-2030F”, has evaluated
the future growth potential of Global Renal Biomarkers Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Renal Biomarkers Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com